Continuing Education Activity

Clonidine is a central alpha-2 adrenergic and imidazoline receptor agonist that lowers blood pressure and heart rate by decreasing sympathetic outflow, leading to vasodilation and improved myocardial perfusion. Clonidine holds Food and Drug Administration–approved indications beyond antihypertensive therapy, including treatment of attention-deficit/hyperactivity disorder in children, management of tics associated with Tourette syndrome, and adjunctive therapy for severe cancer-related pain. This activity reviews the mechanism of action, indications, adverse event profile, toxicity, dosing, drug interactions, and monitoring of clonidine, providing a comprehensive understanding of its pharmacology. Mastery of these aspects enables healthcare professionals to individualize treatment plans, optimize therapeutic outcomes, and minimize adverse events, ensuring safe and effective use of clonidine in diverse patient populations.

Participants in this activity gain knowledge that enhances their ability to evaluate, prescribe, and monitor clonidine therapy effectively. The course emphasizes the importance of collaboration within the interprofessional healthcare team, demonstrating how shared expertise among clinicians and pharmacists improves patient care. By understanding each team member's role in monitoring response, adjusting dosing, and managing potential adverse effects, participants learn to optimize treatment outcomes and ensure patient safety. The program enhances competence in both pharmacological decision-making and team-based care, demonstrating how interprofessional collaboration fosters patient-centered approaches and ultimately leads to improved clinical outcomes for patients receiving clonidine therapy.

Objectives:

• Identify the mechanism of action, Food and Drug Administration–approved and off-label indications, and pharmacologic properties of clonidine.
• Screen patients for contraindications, comorbidities, and risk factors that may impact clonidine therapy.
• Assess the potential adverse reactions associated with clonidine.
• Implement effective collaboration and communication among interprofessional team members to optimize patient outcomes and enhance treatment efficacy for individuals receiving clonidine.

Access free multiple choice questions on this topic.

Indications

Clonidine, approved by the United States Food and Drug Administration (FDA) in 1974, is an antihypertensive agent that functions as an agonist at alpha-adrenergic and imidazoline receptors. This agent lowers blood pressure and heart rate by relaxing the smooth muscle of the arteries and reducing myocardial oxygen demand. Clonidine is classified as an alpha-2 adrenergic agonist.

Food and Drug Administration–Approved Indications

• Management of adult hypertension: Clonidine may be used alone or preferably with simultaneous use of other antihypertensive agents. Clonidine is typically used for treatment-resistant hypertension.[1]
• Treatment of attention-deficit/hyperactivity disorder (ADHD) in children: FDA-approved for the extended-release dose form and extended-release suspension.[2][3][4]
• Management of tics associated with Tourette syndrome.[5][6]
• Adjunct therapy for severe cancer-related pain.[7]

Off-Label Uses

Clonidine is used for withdrawal symptoms from opioids, benzodiazepines, and alcohol, and anxiety.[8] This agent is used explicitly as an adjunct in neonatal opioid withdrawal syndrome.[9][10] Due to the effect of clonidine on the sympathetic nervous system, it has been used off-label in various medical disorders, including the control of hot flashes during menopause, restless leg syndrome, and prophylaxis of vascular migraine headaches. Additionally, a test for phaeochromocytoma is available, known as the clonidine suppression test. In the laboratory, catecholamine levels are measured before and after administering a dose of oral clonidine. In healthy individuals, this test should result in a decrease in circulating catecholamine levels.[7][8][11] The use of clonidine for pediatric hypertension is off-label.[12] According to the American Society of Addiction Medicine and the American Academy of Addiction Psychiatry, for managing stimulant use disorder, clonidine may be considered if the hyperadrenergic state continues despite appropriate management of agitation and neuromuscular hyperactivity with benzodiazepines or other GABAergic agents. Clinicians can consider the addition of alpha-2 adrenergic agonists, such as dexmedetomidine for severe symptoms and clonidine for mild-to-moderate withdrawal symptoms.[13] According to the 2017 American College of Cardiology/American Heart Association guidelines for hypertension, clonidine is typically reserved as a last-line treatment due to its CNS adverse effects, especially in older adults. The abrupt discontinuation of clonidine may induce a hypertensive crisis. Therefore, clonidine must be tapered to avoid rebound hypertension.[14]

Mechanism of Action

Clonidine hydrochloride is an imidazoline derivative that acts centrally on alpha-2 adrenergic receptors as an agonist. The chemical name for clonidine is 2-((2,6-dichlorophenyl) amino)-2-imidazoline hydrochloride.

As an alpha-adrenergic agonist in the nucleus tractus solitarii, clonidine excites a pathway that inhibits excitatory cardiovascular neurons. Clonidine functions as an alpha-adrenergic antagonist in the posterior hypothalamus and medulla, ultimately reducing sympathetic outflow from the central nervous system (CNS). This central inhibition leads to a clinically significant decrease in arterial blood pressure.

One theory regarding clonidine's mechanism of action in pain management is that many pain signals are processed in the dorsal horn of the spinal cord before being transmitted to higher centers of the CNS. There is a release of norepinephrine from the descending inhibitory bulbospinal neurons that binds to alpha-2 receptors in the dorsal horn to decrease afferent pain transmission and produce analgesia. Therefore, drugs such as clonidine that target alpha-2 receptors can influence the transmission of pain.[15]

Epidural clonidine, used as an adjunct to local anesthetics, has 3 different mechanisms of action. First, the stimulation of alpha-2 receptors in the dorsal horn reduces pain transmission. Secondly, clonidine can cause local vasoconstriction that limits vascular removal of local epidural anesthetics. Lastly, clonidine enhances the effects of neuraxial opioids and interacts additively with fentanyl, potentially reducing the dosage of each component by 60% for postoperative analgesia.[16][17] 

The exact mechanism by which clonidine manages ADHD is not clear; however, it is thought to involve alteration of prefrontal cortex brain activity. Clonidine activates alpha-2 receptors, which decrease the firing rate of presynaptic neurons and decrease norepinephrine release into the prefrontal cortex. This process opens potassium channels and lowers the levels of cyclic adenosine monophosphate. Clonidine is believed to improve impulsivity and hyperactivity in individuals with ADHD through this mechanism.[18]

Pharmacokinetics

Absorption: When taken orally, clonidine is quickly absorbed within 3 to 5 hours. In contrast, the extended-release formulation has a slower absorption rate, reaching peak absorption within 4 to 7 hours. The transdermal formulation of clonidine is absorbed steadily over 7 days, with the initial peak plasma concentration (Tmax) occurring between 2 and 3 days. The immediate-release form of clonidine begins to show effects within 30 to 60 minutes, with peak effects occurring between 2 and 4 hours. The effectiveness of clonidine can last up to 8 hours after administration, and similarly, the transdermal form may last for 8 hours after discontinuation.[18]

Distribution: The volume of distribution of clonidine has been reported as 2.1 ± 0.4 L/kg. Clonidine exhibits high lipid solubility and is readily distributed within the central nervous system.[19] The plasma protein binding ranges from 20% to 40%.

Metabolism: Clonidine undergoes enterohepatic recirculation after oral administration.[20] The predominant role of CYP2D6 in the nonrenal clearance of clonidine explains the increase in clearance during pregnancy. Clonidine may therefore be added to the list of CYP2D6 substrates whose pharmacokinetics are altered in pregnancy; however, further studies are needed to validate these findings.[21]

Excretion: Following oral administration of clonidine, approximately 40% to 60% of the dose is recovered in the urine as unchanged drug within 24 hours. Clonidine has a half-life of between 6 and 20 hours. The half-life increases from 17 to 40 hours in cases of renal impairment. 

Administration

Available Dosage Forms and Strengths

Clonidine is available in multiple dosage forms, including immediate-release tablets, extended-release tablets, transdermal patches, and oral suspension. The different formulations are not interchangeable on a milligram-to-milligram basis.

• Transdermal patch (extended-release)

  • Dosage: 0.1, 0.2, and 0.3 mg/d. Change the patch every 7 days.
  • Indications: Hypertension, smoking cessation, cyclosporine nephrotoxicity, menopausal flushing, and opioid withdrawal
• Tablet (immediate-release)

  • Dosage: 0.1, 0.2, and 0.3 mg
  • Indications: Hypertension, acute hypertension, opioid withdrawal, and pheochromocytoma
• Tablet (extended-release)

  • Dosage: 0.1 mg
  • Indications: Alcohol withdrawal, smoking cessation, restless leg syndrome, ADHD, Tourette syndrome, menopausal flushing, dysmenorrhea, postherpetic neuralgia, and psychosis
• Injectable Solution

  • Dosage: 100 and 500 mcg/mL
  • Indications: Epidural infusion form in cancer pain not controlled by opioid analgesics, and as an adjunct in anesthesia
  • The initial dose of 30 mcg/h and titration are necessary for pain management and to minimize potential adverse effects.

Dosing Considerations

Extended-release and immediate-release types of clonidine are not interchangeable. When converting from oral to transdermal clonidine, the following titration schedule is recommended:

• Day 1: Place a transdermal clonidine patch, and administer 100% of the oral dose.
• Day 2: Administer only 50% of the oral dose.
• Day 3: Administer 25% of the oral dose.
• Day 4: The use of the transdermal patch continues without any further oral clonidine.

Specific Patient Populations

Hepatic impairment: No dosage adjustment for hepatic impairment has been provided in the product labeling.

Renal impairment: For patients with renal impairment, it is recommended to start with a low dose and titrate the dose cautiously. The initial dose should be adjusted based on renal function. Monitor carefully for hypotension and bradycardia.[22]

Pregnancy considerations: Reproduction studies in rabbits at doses up to approximately 3 times the oral maximum recommended daily human dose of clonidine showed no evidence of teratogenicity or embryotoxicity. In rats, increased resorptions occurred at doses as low as one-third the oral maximum recommended daily human dose when treatment began 2 months before mating, but not when administered during gestation days 6 to 15 at the same or higher doses. Marked increases in resorptions were observed in mice and rats at much higher doses. No adequate, well-controlled studies exist in pregnant women, and clonidine crosses the placental barrier. According to product labeling, clonidine should be used during pregnancy only if indicated. Pregnant patients should enroll or be encouraged to enroll in the National Pregnancy Registry for ADHD Medications.

Breastfeeding considerations: Clinicians should carefully weigh the risks and benefits of prescribing clonidine to breastfeeding patients. Although adequate human data are limited, there is a potential risk of infant sedation, hypotonia, and apnea. The drug could also theoretically impair breast milk production because of decreased prolactin levels. Due to high serum levels observed in some breastfed infants, potential adverse effects on the infant, and possible negative impacts on lactation, other antihypertensive medications are generally preferred, especially during breastfeeding of a newborn or preterm infant. Although clonidine as a single postpartum dose for neuraxial analgesia may not have been extensively studied, it could reduce the need for other drugs or decrease their doses, and is unlikely to affect breastfeeding significantly. Clinicians should weigh the risks and benefits of prescribing clonidine to breastfeeding patients. Although human data are limited, there is a potential risk of infant sedation, hypotonia, and apnea. Clonidine may also theoretically reduce breast milk production by lowering prolactin levels.[23]

Pediatric patients: The safety and efficacy of clonidine extended-release for ADHD have been demonstrated in pediatric patients aged 6 to 17.[24] For pediatric patients with ADHD, extended-release clonidine should be started at 0.1 mg at bedtime for 1 week, then increased by 0.1 mg/d at weekly intervals until the desired therapeutic effect is achieved. According to the manufacturer's label, the general guidance is to increase the dosage by 0.1 mg/d at weekly intervals, up to a maximum of 0.4 mg/d, administered in 2 divided doses of 0.2 mg each, with the larger portion given at bedtime.

Older patients: The American Geriatrics Society Beers Criteria lists central alpha-2 agonists as potentially inappropriate for use in older adults with hypertension. According to the American Geriatrics Society, clonidine is not recommended as a first-line antihypertensive in older adults due to its high risk of adverse effects, including bradycardia, hypotension, and central nervous system effects, such as sedation.[25]

Adverse Effects

Like other medications, clonidine has the potential for short-term and long-term adverse effects. According to FDA reports, commonly observed reactions include the following:

Common Reactions

• Hypotension
• Abdominal pain
• Headache
• Fatigue
• Nausea
• Emotional instability
• Constipation
• Xerostomia
• Diarrhea
• Sexual dysfunction
• Dizziness
• Sedation

Serious Reactions

• Angioedema
• Depression
• Hypersensitivity
• Atrioventricular block
• Bradycardia
• Syncope
• Severe hypotension

Abrupt discontinuation of clonidine may result in rebound hypertension and withdrawal symptoms.[26]

Other Adverse Drug Reactions

• Fever and headache
• Fatigue
• Bradycardia
• Congestive heart failure
• Decreased sexual activity
• Thrombocytopenia
• Agitation
• Depression is one of the rarely reported adverse effects that can occur with the chronic use of clonidine; however, because of the variety of applications for this medication and also because of its slowly progressive onset, clinicians should monitor patients for signs of depression.[27]

Drug-Drug Interactions

• CNS depressants: Clonidine may enhance central nervous system depression when combined with alcohol, barbiturates, and benzodiazepines, increasing the risks of sedation and significant CNS depression.

• Antihypertensive drugs: The combined use of antihypertensive medications with clonidine can increase the possibility of hypotension. Blood pressure monitoring and dose adjustments are required.

• Drugs affecting conduction: Coadministration of clonidine with digoxin or calcium channel blockers can lead to bradycardia or atrioventricular block due to the effects on conduction pathways, with severe cases requiring hospitalization or pacing.[28]

• Beta-blockers: The combination of beta-blockers with clonidine can cause marked bradycardia, atrioventricular block, or hypotension due to synergistic suppression of sympathetic tone. Abrupt withdrawal of clonidine while on a beta-blocker can trigger severe rebound hypertension, resulting from unopposed alpha-adrenergic activity. Therefore, beta-blockers should be withdrawn several days before tapering clonidine over several weeks.

Contraindications

Absolute contraindications are hypersensitivity to clonidine or excipients. For epidural use, clonidine administration is contraindicated above the C4 dermatome.

Box Warnings (Epidural Clonidine)

• The 500 mcg/mL strength of clonidine should be diluted in an appropriate solution before use. 
• Epidural clonidine is not advised for the management of postpartum, obstetrical, or perioperative pain. The potential for hemodynamic instability, bradycardia, and hypotension, caused by epidural clonidine, may be unacceptable in these patient populations. However, in rare cases involving obstetrical, postpartum, or perioperative patients, the potential benefits may outweigh the associated risks.

Warnings and Precautions

• Dose adjustments are necessary in patients with renal impairment, cardiovascular disease, bradycardia, hypotension, and severe coronary artery disease. Caution is also advised when treating patients with a history of depression, recent myocardial infarction, and syncope.
• There are no absolute drug interaction contraindications listed for clonidine; however, there are numerous agents that require caution, and the clinician is recommended to perform thorough medication reconciliation and enlist the services of a pharmacist if necessary.[29]
• The drug should not be discontinued suddenly, as this may result in rebound hypertension and withdrawal symptoms.
• Rare cases of hypertensive encephalopathy, stroke, and death have been reported. Clonidine should be tapered over several weeks, with beta-blockers discontinued several days earlier. Rebound hypertension can be reversed with oral clonidine or intravenous phentolamine. In children, vomiting from common illnesses may precipitate withdrawal-related hypertensive episodes.

Monitoring

Clonidine Black Box Warning and Safety Considerations

• Proper use: The 500?mcg/mL formulation should be diluted in an appropriate solution before administration.
• Obstetrical, postpartum, or perioperative use: The risks and benefits must be carefully weighed. Epidural clonidine is not recommended for obstetrical and postpartum perioperative pain management due to an increased risk of hemodynamic instabilities, including hypotension and bradycardia.
• Potential for misuse (in combination with other CNS depressants): Although clonidine is commonly used in detoxification to manage withdrawal symptoms of opioid addiction, it carries a rare risk of misuse and warrants appropriate monitoring.[30]

In many cases, clonidine use does not fit the typical addiction profile, particularly because most individuals who misuse it do not perceive their behavior as wrongful, given that it is a prescription medication. Clonidine is not classified by the United States government as a medication with high abuse potential. As a result, it has fewer restrictions, and it is less likely to be abused. Unfortunately, much of clonidine misuse starts in rehabilitation centers, as it is a common medication for opioid and alcohol withdrawal treatment. As it helps reduce withdrawal symptoms and cravings, clinicians should evaluate their concerns about the potential of trading addictions.[31]

Misuse is rare and is primarily a polysubstance phenomenon involving excessive opioids or benzodiazepines to avoid synergistic effects and potent sedation. Patients should be educated, high-risk drug combinations should be avoided, and medications should be tapered rather than discontinued abruptly.

Patients should also be informed and screened for signs of clonidine dependency, as outlined below:

• Feeling an intense urge to take clonidine [30]
• Feeling the need to use clonidine regularly
• Increasing the dose to achieve the same effect
• Ensuring a constant backup supply of clonidine
• Spending more on clonidine than one can afford
• Feeling unable to imagine stopping clonidine
• Experiencing withdrawal symptoms, such as nausea, vomiting, dizziness, headache, insomnia, restlessness, or anxiety, when attempting to discontinue the medication [3]

Most behaviors that may appear to suggest clonidine addiction are more explained by its role in controlling hyperadrenergic symptoms during opioid or alcohol withdrawal, or by the need to avoid rebound hypertension with missed doses. Actual misuse is infrequent and typically occurs in the context of combining clonidine with other central nervous system depressants, such as opioids or benzodiazepines, in excessive amounts to enhance sedation. Physiological dependence and withdrawal symptoms are expected with chronic clonidine use. Abrupt cessation can be life-threatening due to severe rebound hypertension and should not be mistaken for addiction.

Toxicity

Signs and Symptoms of Overdose

In clonidine overdose, cardiovascular effects often begin with early hypertension, likely due to initial peripheral alpha-2 adrenergic stimulation causing vasoconstriction, and progress to hypotension, bradycardia, and, in severe cases, reversible cardiac conduction defects or arrhythmias. Respiratory involvement may manifest as depression or apnea. Neurologic features include drowsiness, irritability, decreased or absent reflexes, coma, and seizures. Hypothermia and miosis have been reported.[32] A retrospective review from 2014 to 2020 examined 111 pediatric clonidine poisonings, mostly in young children or adolescents, with 70% involving clonidine alone. Abnormal observations included bradycardia in 72%, hypotension in 69%, and a Glasgow Coma Scale score of less than 9 in 4%. Severe bradycardia occurred in 12% and was more frequent in young children. Interventions included naloxone, atropine, or rare intubation. Ingestion of less than 5 mcg/kg may result in moderate or severe toxicity, and such cases may not require admission.[33]

Management of Overdose

There is no specific antidote for clonidine overdose, and treatment is primarily supportive. The airway should be protected. Bradycardia may be managed with atropine, whereas hypotension can be addressed with intravenous fluids and, if necessary, vasopressor agents. Naloxone may serve as a helpful adjunct in cases of clonidine-induced respiratory depression, hypotension, or coma, though blood pressure should be closely monitored given the potential for paradoxical hypertension. Dialysis is unlikely to increase the elimination of clonidine. Case reports have suggested the use of naloxone to counteract clonidine's sedative effects.[34]

Enhancing Healthcare Team Outcomes

Clonidine is prescribed by a range of clinicians, including primary care clinicians, cardiologists, psychiatrists, and internists. In addition to treating hypertension, clonidine has multiple off-label uses, such as managing withdrawal symptoms from opioids, benzodiazepines, and alcohol, analgesia, and treatment of anxiety, insomnia, and posttraumatic stress disorder.

Although clonidine is generally considered safe, it is important to review potential contraindications and adverse effects with a pharmacist. The drug is also known to cause physical and psychological dependence.[35] These considerations, along with its clinical implications, highlight the importance of an interprofessional team approach. Clinicians prescribe the drug as they deem appropriate. Nurses can review administration and dosing with the patient and answer any questions they may have. The pharmacist performs medication reconciliation, reinforces dosage counseling, and advises the patient regarding potential adverse events that need to be addressed promptly. If any member of the team becomes aware of an adverse event, therapeutic failure, or misuse of the drug, they must immediately alert all members of the interprofessional team so that appropriate corrective action can take place. This interprofessional approach to medication therapy, which involves the coordinated efforts of clinicians and pharmacists, can optimize clinical outcomes with clonidine while minimizing potential adverse events.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Tian Z, Vollmer Barbosa C, Lang H, Bauersachs J, Melk A, Schmidt BMW. Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res. 2024 Feb 27;120(1):108-119. [PubMed: 37890022]

2.

Groom MJ, Cortese S. Current Pharmacological Treatments for ADHD. Curr Top Behav Neurosci. 2022;57:19-50. [PubMed: 35507282]

3.

Ommi D, Teymourian H, Zali A, Ashrafi F, Jabbary Moghaddam M, Mirkheshti A. Effects of Clonidine Premedication on Intraoperative Blood Loss in Patients With and Without Opium Addiction During Elective Femoral Fracture Surgeries. Anesth Pain Med. 2015 Aug;5(4):e23626. [PMC free article: PMC4602228] [PubMed: 26473101]

4.

Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W., SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019 Oct;144(4) [PMC free article: PMC7067282] [PubMed: 31570648]

5.

Joo SW, Kim HW. Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release. Psychiatry Investig. 2018 Jan;15(1):90-93. [PMC free article: PMC5795037] [PubMed: 29422931]

6.

Zhao Z, Qian Y, Du Y, Chen H, He J, Chen Y, Wang X, Mai J, Sun S, Wang H, Jiao F. Efficacy of Clonidine Adhesive Patch for Patients With Tourette Syndrome: A Randomized, Double-blind, Placebo-Controlled, Multicenter Clinical Trial. 2024 Sep-Oct 01Clin Neuropharmacol. 47(5):150-156. [PMC free article: PMC11446511] [PubMed: 39258554]

7.

Khakurel S, Sapkota S, Karki AJ. Analgesic Effect of Caudal Bupivacaine with or without Clonidine in Pediatric Patient. J Nepal Health Res Counc. 2019 Jan 28;16(41):428-433. [PubMed: 30739935]

8.

Bello M, Oger S, Bedon-Carte S, Vielstadte C, Leo F, Zaouter C, Ouattara A. Effect of opioid-free anaesthesia on postoperative epidural ropivacaine requirement after thoracic surgery: A retrospective unmatched case-control study. Anaesth Crit Care Pain Med. 2019 Oct;38(5):499-505. [PubMed: 30731138]

9.

Byerley EM, Mohamed MW, Grindeland CJ, Muzzy Williamson JD. Neonatal Abstinence Syndrome Practices in the United States. J Pediatr Pharmacol Ther. 2021;26(6):577-583. [PMC free article: PMC8372852] [PubMed: 34421406]

10.

Bada HS, Westgate PM, Sithisarn T, Yolton K, Charnigo R, Pourcyrous M, Tang F, Gibson J, Shearer-Miller J, Giannone P, Leggas M. Clonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial. Pediatrics. 2024 Nov 01;154(5) [PMC free article: PMC11524040] [PubMed: 39403061]

11.

Achote E, Arroyo Ripoll OF, Araujo-Castro M. Update on the diagnosis of the pheochromocytoma. Hipertens Riesgo Vasc. 2025 Jan-Mar;42(1):43-51. [PubMed: 39394015]

12.

Thomas J, Stonebrook E, Kallash M. Pediatric hypertension: Review of the definition, diagnosis, and initial management. Int J Pediatr Adolesc Med. 2022 Mar;9(1):1-6. [PMC free article: PMC9072228] [PubMed: 35573063]

13.

Clinical Guideline Committee (CGC) Members; ASAM Team; AAAP Team; IRETA Team. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. 2024 May-Jun 01J Addict Med. 18(1S Suppl 1):1-56. [PMC free article: PMC11105801] [PubMed: 38669101]

14.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. [PubMed: 29133356]

15.

Schubert AK, Wiesmann T, Wulf H, Obert JDA, Eberhart L, Volk T, Dinges HC. The analgetic effect of adjuvants in local infiltration analgesia - a systematic review with network meta-analysis of randomized trials. J Clin Anesth. 2024 Oct;97:111531. [PubMed: 39003958]

16.

Xuan C, Yan W, Wang D, Li C, Ma H, Mueller A, Wang J. The Facilitatory Effects of Adjuvant Pharmaceutics to Prolong the Duration of Local Anesthetic for Peripheral Nerve Block: A Systematic Review and Network Meta-analysis. Anesth Analg. 2021 Sep 01;133(3):620-629. [PubMed: 34153021]

17.

Paech MJ, Pavy TJ, Orlikowski CE, Yeo ST, Banks SL, Evans SF, Henderson J. Postcesarean analgesia with spinal morphine, clonidine, or their combination. Anesth Analg. 2004 May;98(5):1460-6, table of contents. [PubMed: 15105231]

18.

Neuchat EE, Bocklud BE, Kingsley K, Barham WT, Luther PM, Ahmadzadeh S, Shekoohi S, Cornett EM, Kaye AD. The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review. Neurol Int. 2023 May 22;15(2):697-707. [PMC free article: PMC10204383] [PubMed: 37218982]

19.

Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, Lewis TR, Yaster M, Gauda EB. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009 May;123(5):e849-56. [PMC free article: PMC2746902] [PubMed: 19398463]

20.

Mehta HR, Patel IK, Patel NH, Patel DM, Parmar AB. Implication of enterohepatic re-circulation on single dose bioequivalence evaluation of two brands of clonidine hydrochloride tablets in healthy human volunteers. Indian J Pharm Sci. 2009 Sep;71(5):515-20. [PMC free article: PMC2866342] [PubMed: 20502569]

21.

Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. [PMC free article: PMC2939473] [PubMed: 20570945]

22.

Kuzmin OB, Buchneva NN, Zhezha VV, Serdyuk SV. [Uncontrolled Arterial Hypertension: Kidney, Neurohormonal Imbalance, and Approaches to Antihypertensive Drug Therapy]. Kardiologiia. 2019 Dec 11;59(12):64-71. [PubMed: 31849313]

23.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Nov 15, 2024. Clonidine. [PubMed: 30000689]

24.

Yellepeddi V, Bayless S, Parrot M, Sherwin CM. Optimal Dosing Recommendations of Clonidine in Pediatrics Using Physiologically Based Pharmacokinetic Modeling. J Pediatr Pharmacol Ther. 2024 Dec;29(6):636-644. [PMC free article: PMC11627573] [PubMed: 39659862]

25.

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PMC free article: PMC12478568] [PubMed: 37139824]

26.

Cao C, Lorenz ML, Sojka P, Brindle AW, Topor LS. Hypertensive Crisis in a Pediatric Patient Experiencing Clonidine Withdrawal. Case Rep Pediatr. 2022;2022:9005063. [PMC free article: PMC8964232] [PubMed: 35359336]

27.

Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):424-32. [PMC free article: PMC8101845] [PubMed: 12461307]

28.

Handler J. Adverse effects using combined rate-slowing antihypertensive agents. J Clin Hypertens (Greenwich). 2011 Jul;13(7):529-32. [PMC free article: PMC8816423] [PubMed: 21762367]

29.

Carpenter M, Berry H, Pelletier AL. Clinically Relevant Drug-Drug Interactions in Primary Care. Am Fam Physician. 2019 May 01;99(9):558-564. [PubMed: 31038898]

30.

Townsend EA, Negus SS, Banks ML. Medications Development for Treatment of Opioid Use Disorder. Cold Spring Harb Perspect Med. 2021 Jan 04;11(1) [PMC free article: PMC7778216] [PubMed: 31932466]

31.

Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M. Pharmacological therapies for management of opium withdrawal. Cochrane Database Syst Rev. 2018 Jun 21;6(6):CD007522. [PMC free article: PMC6513031] [PubMed: 29929212]

32.

Isbister GK, Heppell SP, Page CB, Ryan NM. Adult clonidine overdose: prolonged bradycardia and central nervous system depression, but not severe toxicity. Clin Toxicol (Phila). 2017 Mar;55(3):187-192. [PubMed: 28107093]

33.

Duong C, Lovett C, Downes MA, Isbister GK. Reality of clonidine poisoning in children and adolescents. J Paediatr Child Health. 2023 Jun;59(6):827-832. [PMC free article: PMC10946816] [PubMed: 37036115]

34.

Swift A, Wilson M. Reversal of the effects of clonidine using naloxone. Anaesth Rep. 2019 Jan-Jun;7(1):4-6. [PMC free article: PMC6931288] [PubMed: 32051935]

35.

Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. J Med Toxicol. 2018 Dec;14(4):306-322. [PMC free article: PMC6242798] [PubMed: 30377951]

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.